Rituximab Biosimilar

Pipeline

Status by Indication[2][1]

Competition

Competitive Landscape

Diffuse Large B-Cell LymphomaFollicular LymphomaLymphoma, Large B-Cell, Diffuse

332 competitors in Diffuse Large B-Cell Lymphoma

#DrugCompanyPhaseTrials

1

Rituxan

Roche

Phase 3

1432

Adriamycin

Pfizer

Phase 3

393

Gemzar

Johnson & Johnson

Phase 3

194

Gazyva

Roche

Phase 3

185

Eloxatin

Teva

Phase 3

176

Rayos

RRoxane Laboratories

Phase 3

577

Cytoxan

BBaxter Healthcare Corporation

Phase 3

688

Revlimid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

299

COLUMVI

Roche

Phase 3

1010

Cytosar

Teva

Phase 3

9Show 42 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Diffuse Large B-Cell Lymphoma1 trial

A Randomized, Open-Label, Multicenter, Phase 3 Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP Versus R-CHOP in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) (waveLINE-010)

Recruiting·Merck & Co.·Phase 3·NCT06717347·1,046 enrolled

Lymphoma, Large B-Cell, Diffuse1 trial

A Randomized, Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) Plus R-CHP Versus Polatuzumab Vedotin Plus R-CHP in Treatment-naïve Participants With GCB Subtype of Diffuse Large B-cell Lymphoma (DLBCL)

Recruiting·Merck & Co.·Phase 2·NCT06890884·594 enrolled

Follicular Lymphoma1 trial

A Phase 2/3 Randomized, Open-label Study of MK-1045 in Combination With Rituximab in Participants With 1L Follicular Lymphoma

Recruiting·Merck & Co.·Preclinical·NCT07634471·960 enrolled

Details

Drug Info

Related News